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Eligibility for co-trimoxazole 
prophylaxis among adult HIV-infected 
patients in South Africa 
To the Editor: Co-trimoxazole (fixed-dose trimethoprim-sulfa-
methoxazole) is a broad-spectrum antibiotic used to prevent 
opportunistic infections in patients with HIV infection. Primary 
prophylaxis with co-trimoxazole has been shown to decrease 
hospitalisation, morbidity and mortality among people living with 
HIV, primarily by decreasing rates of malaria, pneumonia, diarrhoea, 
Pneumocystis pneumonia, toxoplasmosis and severe bacterial 
infections.[1-4] Co-trimoxazole is inexpensive and widely available. In 
standard adult treatment guidelines and essential medicine lists in 
South Africa (SA), the current recommendation is that co-trimoxazole 
should be provided for HIV-infected patients with a CD4+ count 
˂200 cells/µL, HIV/tuberculosis (TB) co-infection and/or advanced 
HIV disease (World Health Organization (WHO) stage 3 or 4).
Because of expanded access and progression towards initiation of 
antiretroviral treatment (ART), the WHO issued updated guidelines 
for co-trimoxazole prophylaxis in 2014.[5] These guidelines recommend 
co-trimoxazole prophylaxis for adults (including pregnant women) 
with severe or advanced HIV clinical disease (WHO stage 3 or 4) 
and/or with a CD4+ count ≤350 cells/µL. In settings with a high 
prevalence of malaria and/or severe bacterial infections, prophylaxis 
is recommended for all patients regardless of WHO clinical stage 
or CD4+ cell count. However, the timing of discontinuation of 
co-trimoxazole prophylaxis may vary and is dependent on the malarial/
bacterial infection burden in different settings.[5] Therefore, the current 
WHO guidance should be adapted in the context of a country-specific 
epidemiological profile and priorities. 
The impact and benefit of co-trimoxazole prophylaxis on morbi-
dity and mortality among HIV-infected patients with a CD4+ count 
≤350 cells/µL in regions with high infectious disease burdens (irre-
spective of CD4+ count) have been shown in a good- quality syste matic 
review and meta-analysis that included both rando m ised controlled 
trials (RCTs) and observational cohort studies.[6] This extensive syste-
matic review by Suthar et al.[6] showed that co-trimoxazole prophy laxis 
reduced the rate of death when initiated at CD4+ counts ≤350 cells/ µL 
with ART in populations in Africa and Asia. Co-trimoxazole prophy-
laxis in ART-naive patients with CD4+ counts >350 cells/ µL reduced 
the rate of death and malaria, and continu ation of prophylaxis after 
ART-induced recovery with CD4+ counts >350 cells/µL reduced hos-
pital admission, pneumonia, malaria and diarrhoea in African popula-
tions (SA, Zimbabwe, Uganda, Malawi, Mozambique and Ethiopia).[6] 
While this review largely informed the 2014 WHO guideline update, 
the findings need to be interpreted in the context of studies included 
and the varied epidemiological profile across middle- and low-income 
countries. There were only 2 relatively small RCTs with very few events 
of key endpoints; therefore, the finding of non-significance was likely 
(e.g. total of ~5 deaths in both arms from both trials).[7,8] One of the 
2 studies was unblinded, and the follow-up in the other study was 
only 4 months. Ongoing co-trimox azole prophylaxis was better than 
discontinuation of the drug at CD4+ counts >200 cells/µL for 3 end-
points with an adequate number of events (pneumonia, diarrhoea and 
malaria). Furthermore, 8 of 9 studies were conducted in countries with 
a high burden of malaria and bacterial and parasitic diseases, which is 
generalisable to the SA context.[9] Although season al malaria occurs in 
the north-eastern parts of SA, the incidence of malaria mortality and 
morbidity has declined remarkably over time (˂10 000 cases annually 
for the past 10 years).[10] In contrast, in Uganda, >9 million confirmed 
cases of malaria were reported in the public health sector in 2015.[9] In this 
review, further stratification of the impact of co-trimoxazole prophylaxis 
at CD4+ counts ˂200 cells/µL v. 200 - 350 cells/µL was not available. 
Lower bacterial resistance to co-trimoxazole is possible among popu-
lations included in this review, while resistance to co-trimoxazole in 
SA is common in patients with community-acquired bacterial 
infections.[11-13] This potential risk of resistance compounded by 
the lack of long-term toxicity data needs to be weighed against 
recommending prophylaxis in populations where benefit has not 
been established.
Local observational studies suggest no benefit of co-trimoxazole 
prophylaxis with a CD4+ count >200 cells/µL or in patients who 
were not WHO clinical stage 3 or 4.[14,15] In an observational cohort 
of patients attending the adult HIV clinics at the University of Cape 
Town, SA, the effect of prophylactic low-dose co-trimoxazole on 
survival and morbidity was examined over a 5-year follow-up period. 
Co-trimoxazole reduced the hazards of mortality by ~44% and the 
incidence of severe HIV-related illnesses by ~48% in patients with 
evidence of advanced immunosuppression (WHO stage 3 or 4) or 
laboratory measurement of total lymphocyte count ˂1 250 × 106/L or 
CD4+ count ˂200 cells/µL. However, no beneficial effect was seen in 
patients with WHO clinical stage 2 or CD4+ count 200 - 500 cells/µL. 
A potential limitation of this study was that the sample size of patients 
with a CD4+ count 200 - 500 cells/µL receiving co-trimoxazole was 
small and may have been underpowered to observe a significant 
benefit. In this study, patients on ART were excluded.[14] In another 
SA cohort study by Hoffmann et al.,[15] examining co-trimoxazole 
effectiveness in reducing mortality risk during ART among persons 
with a CD4+ count >200 cells/µL and varying WHO clinical stages, 
overall co-trimoxazole prophylaxis reduced mortality by 36% across 
all CD4+ count strata. Analysis stratified by baseline CD4+ count 
showed a similar reduction in mortality risk among persons with a 
CD4+ count ˂200 cells/µL, but no statistically significant association 
was found between co-trimoxazole prophylaxis and survival in the 
subgroup of persons with a CD4+ count >200 - 350 cells/µL, CD4+ 
count >350 cells/µL and WHO stage 1 or 2 disease. However, the 
findings of this study need to be interpreted cautiously for the following 
reasons: the group with a CD4+ count >350 cells/µL was small (n=917) 
and might not have had enough events to draw inferences; the study 
population was a cohort of miners and might not have been potentially 
representative of the SA population; and, being a non-randomised 
study, residual confounding might have been a potential limitation. 
An earlier Cochrane review established the benefit of initiating 
prophylaxis at a CD4+ count ˂200 cells/µL in those with stage 2, 3 or 4 
HIV disease (including TB), and discontinuation once the CD4+ count 
was >200 cells/µL for >6 months.[16] There was a reduction of ~31% in 
mortality, 27% in morbid events and 55% in hospitalisation. Significant 
reductions were also detected for bacterial and parasitic infections and 
for Pneumocystis jirovecii pneumonia. 
Considering the above-mentioned evidence gaps and lack of 
generalisability of studies to SA, the current National Essential 
Medicines List Committee and Adult Hospital-Level Technical 
Sub-committee do not support the implementation of the updated 
guidance by the WHO for co-trimoxazole prophylaxis among adult 
HIV-infected patients. Efforts should be directed towards exploring 
several research gaps. The impact of co-trimoxazole prophylaxis on 
morbidity and mortality at higher CD4+ counts in low-malaria-
burden areas needs to be investigated further. More data are needed 
on timing of co-trimoxazole cessation in HIV and TB co-infection 
in our context. 
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